Navigation Links
Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
Date:12/6/2007

SAN FRANCISCO, Dec. 6 /PRNewswire/ -- Epiphany Biosciences announced today, the initiation of a Phase 2 clinical trial with valomaciclovir (EPB-348) for the treatment and management of acute infectious mononucleosis. Currently, there are no approved therapeutics for the treatment for this debilitating condition or any other disease caused by the Epstein-Barr virus (EBV)

"Valomaciclovir has shown a broad spectrum of anti-viral activity, including inhibition of viral replication of herpes zoster and EBV," said Fred Volinsky, MD, Chief Executive Officer. "EBV has been implicated in a number of chronic and transplant-related diseases. This initial study in acute mononucleosis will set the stage for broader indications involving EBV as an etiologic agent. We are pleased to be working with the University of Minnesota on this important project".

"EBV is a highly prevalent virus, with up to 95% of middle-aged adults possessing evidence of viral exposure according to CDC surveillance data," stated Brian Murphy, MD, Chief Medical Officer. "Mononucleosis can severely undermine quality-of-life and the acute EBV infection may lead to other long-term medical sequelae. This double-blind, placebo-controlled, clinical trial will examine fluctuations in viral load as influenced by valomaciclovir as well as assess symptom scores."

"Our laboratory has found valomaciclovir to be a very potent anti-viral agent against EBV", reported Dr. Henry H. Balfour, Jr., Professor of Pediatrics and Laboratory Medicine and Pathology at the University of Minnesota, who is principal investigator for the study. "If this proof of concept study is successful, further large scale studies are warranted. We urgently need a solution for this disease that can severely impact the lives of young adults."

The acute mononucleosis study at the University of Minnesota will mark the first of several planned studies of valomaciclovir against EBV related diseases. Comparative anti-EBV
'/>"/>

SOURCE Epiphany Biosciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
8. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
9. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
10. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
11. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... HARBIN, China, Oct. 25, 2011 /PRNewswire-Asia/ -- China Botanic ... Botanic" or the "Company"), a developer, manufacturer and distributor ... in China, today announced that the Company has recently ... in the field of Traditional Chinese Medicine (TCM) and ...
... 25, 2011 Merz Pharmaceuticals, LLC, today announced that ... profiles of Xeomin® (incobotulinumtoxinA), a botulinum toxin type A ... (eyelid spasms) will be presented at the 115th Annual ... Orlando, Fla. These data include an extension ...
Cached Medicine Technology:China Botanic Hosts Technical Exchange for Industry Research Experts 2China Botanic Hosts Technical Exchange for Industry Research Experts 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 2Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 4Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 5Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 6Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 7Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 8
(Date:4/24/2014)... corresponding terminology, and the relevance of palliation in ... on randomized controlled trials (RCTs). This is the ... for Quality and Efficiency in Health Care (IQWiG), ... , Together with external experts, IQWiG analysed studies ... cancer, malignant melanoma, and pancreatic cancer. For this ...
(Date:4/24/2014)... Dartmouth has been awarded one of 30 grants ... a Lead Academic Participating Site in its new ... are a select groups of investigators charged with distributing ... groups., The NCTN grant system reflects recommendations from a ... operations to achieve four goals:, Faster design, ...
(Date:4/23/2014)... Massachusetts General Hospital (MGH) investigators may lead to greater ... serious medical problem use of fecal material from ... Clostridium difficile ( C. difficile ) bacteria. ... journal Clinical Infectious Diseases , the researchers report ... unrelated to patients was as successful in curing recurrent ...
(Date:4/23/2014)... John J. O,Shea, M.D., scientific director at the National ... has been named the 2014 recipient of the Ross ... peer-reviewed, open-access journal Molecular Medicine . The award ... York Academy of Sciences in Manhattan, followed by scientific ... is part of the National Institutes of Health. , ...
(Date:4/23/2014)... Purdue University researchers have identified an important enzyme pathway ... or too few chromosomes, a condition that has been ... Hall, associate professor of biochemistry, found that near the ... an enzyme that ensures any breaks in DNA are ... the genome to daughter cells. This process helps safeguard ...
Breaking Medicine News(10 mins):Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... Texas, Feb. 12 Benjamin M. Cutler, ... Inc. (USHEALTH), a leading,national health insurer providing ... self-employed, announced today the promotion of Konrad ... Officer. In this,expanded role, Kober will oversee ...
... 7 Million Shares Shorted Since March 2006 According to ... ... BioElectronics,Corporation (Pink Sheets: BIEL) announced today that BUYINS.NET, http://www.buyins.net, ... sale data to February 2008. From March 2006 to,February 2008 ...
... a set of cues that we then use to make ... service or more expensive candles smell better. However, this set ... learn and recognize other real, positive qualities that are indicated ... April issue of the Journal of Consumer Research. , ...
... celebrities and,socialites have flocked to France for their ... and urban dwellers alike have,to go no further ... oral,care., (Photo: http://www.newscom.com/cgi-bin/prnh/20080212/LATU026 ), Elgydium(R), ... three,decades, has been available in the U.S. on ...
... Su Salud. Su Voz., Campaign to Address Lack of Public Awareness ... to File Medicare Quality of Care Complaints, ... join leaders of health care organizations and senior,groups, along with public ... Salud. Su Voz. Partnership to educate Latino,seniors about their right to ...
... DENVER, Feb. 12 PSI, a leading provider ... today the,signing of a contract with the Ohio ... delivering new hire reporting services for the State ... The new contract will run,for an initial period ...
Cached Medicine News:Health News:USHEALTH Group Announces Appointment of Executive Vice President 2Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 2Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 3Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 4Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 5Health News:BioElectronics Corporation (BIEL) SqueezeTrigger Price is $0.11 6Health News:Old dogs: Prior knowledge affects how consumers accept new information 2Health News:A Favorite in France, Elgydium(R) Toothpaste Makes Entrance Into the U.S. Market 2Health News:Milly Quezada, 'Queen of Merengue,' to Launch Partnership to Educate Latino Seniors About Health Care Rights 2Health News:Milly Quezada, 'Queen of Merengue,' to Launch Partnership to Educate Latino Seniors About Health Care Rights 3Health News:Ohio Selects Policy Studies Inc. (PSI) to Continue Operating Its New Hire Reporting Program 2
... Multi frequency and multigate ... detection and fitted with ... tests for hemodynamic evaluation. ... as well for routine ...
The Spencer Technologies PMD 100 (TCD 100M) is the worlds first stand-alone digital transcranial doppler system....
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
The vertebral body replacement (VBR) is used for the anterior thoracic and lumbar spine. It is intended for use in the thoracic and lumbar spine to replace a collapsed, damaged, or unstable vertebral...
Medicine Products: